Bluejay Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver (EASL) Congress 2024
SAN MATEO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics today announced it will present new data from its ongoing Phase 2 trial evaluating the potential of BJT-778, an investigational anti-HBsAg monoclonal antibody (mAb) that acts against hepatitis B surface antigen, for the treatment of chronic hepatitis D (CHD) at the European Association for the Study of the Liver (EASL) conference taking place June 5-8, in Milan, Italy.
- SAN MATEO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics today announced it will present new data from its ongoing Phase 2 trial evaluating the potential of BJT-778, an investigational anti-HBsAg monoclonal antibody (mAb) that acts against hepatitis B surface antigen, for the treatment of chronic hepatitis D (CHD) at the European Association for the Study of the Liver (EASL) conference taking place June 5-8, in Milan, Italy.
- Bluejay will also present several posters describing the preclinical profile of BJT-778, its mechanisms of action, and its pharmacokinetics and safety profile in healthy volunteers.
- Four abstracts have been selected for presentation, including a late-breaker poster presentation that will highlight the safety, tolerability, and antiviral activity data from the Phase 2 trial evaluating BJT-778 for the treatment of chronic hepatitis delta virus (HDV).
- Additional presentations will focus on the safety and pharmacokinetic profile of BJT-778 in healthy volunteers, the preclinical profile of BJT-778, including its affinity against HBsAg, neutralizing activity against hepatitis B and D viruses, and its pan-genotypic activity, and BJT-778’s preclinical immunomodulatory activity, showcasing its potential for enhancing antiviral T cells functions to potentially clear HBV infection.